This study will last approximately 4 years. Screening will last for approximately 2 weeks. Stage 1, where subjects will be randomized in a 2:1 ratio to OT-101 Ophthalmic Solution or placebo, will last approximately 3 years. Stage 2, where subjects previously assigned to OT-101 Ophthalmic Solution will be re-randomized to either continue with OT-101 Ophthalmic Solution or switch to placebo and subjects previously assigned to placebo will continue with placebo, will last approximately 1 year. Subjects will be asked to undergo visual acuity testing and intraocular examinations at visits every 6 months. Ocular imaging will be performed on a yearly basis.